Clinical Research Papers:

High truncated-O-glycan score predicts adverse clinical outcome in patients with localized clear-cell renal cell carcinoma after surgery

SonTung NguyenHoang, Yidong Liu, Le Xu, Lin Zhou, Yuan Chang, Qiang Fu, Zheng Liu, Zongming Lin _ and Jiejie Xu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:80083-80092. https://doi.org/10.18632/oncotarget.15900

Metrics: PDF 1549 views  |   HTML 2031 views  |   ?  


SonTung NguyenHoang1,*, Yidong Liu2,*, Le Xu3,*, Lin Zhou1, Yuan Chang1, Qiang Fu2, Zheng Liu2, Zongming Lin1 and Jiejie Xu2

1 Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China

2 Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China

3 Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

* These authors have contributed equally to this work

Correspondence to:

Zongming Lin, email:

Jiejie Xu, email:

Keywords: localized clear-cell renal cell carcinoma, truncated O-glycans, overall survival, recurrence-free survival, prognosticator

Received: September 07, 2016 Accepted: February 20, 2017 Published: March 04, 2017


Truncated O-glycans, including Tn-antigen, sTn-antigen, T-antigen, sT-antigen, are incomplete glycosylated structures and their expression occur frequently in tumor tissue. The study aims to evaluate the abundance of each truncated O-glycans and its clinical significance in postoperative patients with localized clear-cell renal cell carcinoma (ccRCC). We used immunohistochemical testing to analyze the expression of truncated O-glycans in tumor specimens from 401 patients with localized ccRCC. Truncated-O-glycan score was built by integrating the expression level of Tn-, sTn- and sT-antigen. Kaplan-Meier survival and Cox regression analysis were done to compare clinical outcomes in subgroups. Receiver operating characteristic (ROC) was applied to assess the impact of prognostic factors on overall survival (OS) and recurrence-free survival (RFS). The results identified Tn-, sTn-, sT-antigen as independent prognosticators. The OS and RFS were shortened among the 198 (49.4%) patients with high Truncated-O-glycan score than among the 203 (50.6%) patients with low score (hazard ratio for OS, 7.060; 95% confidence interval [CI]: 2.765 to 18.027; p <0.001; for RFS, 4.612; 95% CI: 2.141 to 9.931; p <0.001). There is no difference between low-risk patients and high-risk patients in low score group (p = 0.987). High-risk patients with low score showed a better prognosis than low-risk patient with high score (p = 0.029). The Truncated-O-glycan score showed better prognostic value for OS (AUC: 0.739, p = 0.003) and RFS (AUC: 0.719, p = 0.003) than TNM stage. In summary, the high Truncated-O-glycan score could predict adverse clinical outcome in localized ccRCC patients after surgery.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15900